Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00724191|
Recruitment Status : Active, not recruiting
First Posted : July 29, 2008
Last Update Posted : May 11, 2018
|Condition or disease||Intervention/treatment|
|Brain Tumors||Procedure: MRI|
|Study Type :||Observational|
|Estimated Enrollment :||190 participants|
|Official Title:||Quantitation of Human Brain Tumor Therapy Response by MR|
|Study Start Date :||September 1999|
|Estimated Primary Completion Date :||March 2022|
|Estimated Study Completion Date :||March 2022|
Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
- MRI metrics for brain tumor response [ Time Frame: approximately 1 year ]New treatment response MRI metrics derived from change in water diffusion and perfusion from pre-treatment to mid-treatment will be compared to traditional response metrics measured 4 weeks after completion of standard of care chemoradiation for their prediction of patient outcomes and overall survival. The new response metrics are not only measured earlier, but are also quantitative measures for the fraction of tumor exhibiting significant change in diffusion and perfusion assessed on a voxel-by-voxel basis, as well as the volume of dense tumor assessed by analysis of diffusion/perfusion histograms measured over the whole tumor.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724191
|United States, Michigan|
|Univeristy of Michigan Health System|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Thomas L. Chenevert, Ph.D||University of Michigan|